Last reviewed · How we verify
phenylephrine infusion
At a glance
| Generic name | phenylephrine infusion |
|---|---|
| Also known as | Drug by Hefeng Pharmaceutical Co, Shanghai, China. |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia (PHASE2, PHASE3)
- The GUARDIAN Pilot Trial (NA)
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery (PHASE4)
- Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury (NA)
- Deciphering Preserved Autonomic Function After Multiple Sclerosis (NA)
- Longitudinal Autonomic Characterization as a Predictor for Secondary Medical Complications Post-SCI (NA)
- Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock (PHASE3)
- Deciphering Preserved Autonomic Function After Spinal Cord Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- phenylephrine infusion CI brief — competitive landscape report
- phenylephrine infusion updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI